D-2-Hydroxyglutarate (D-2-HG) is an oncometabolite that induces cancer cell survival and growth. D-2-HG is produced by mutations in isocitrate dehydrogenases 1 and 2. L-2-HG has different roles than the D-form, and chiral discrimination is important for elucidating the exact roles of the 2-HG enantiomers. In this study, an analytical method for 2-HG enantiomers was developed using on-line heart-cutting two-dimensional liquid chromatography (2D-LC) with fluorescence detection. Fluorescence derivatization of 2-HG with 4-nitro-7-piperazino-2,1,3-benzoxadiazole (NBD-PZ) was performed using 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride, a hydrophilic condensing reagent, at 70 °C for 30 min. The first dimension on the octadecylsilyl column was aimed at separating NBD-PZ-2-HG from other compounds obtained derivatization or from biological fluids. The NBD-PZ-2-HG peak was fractionated into a sample loop and automatically injected into the second dimension. In the second dimension, a CHIRALPAK IC column separated NBD-PZ-D- and L-2-HG with a resolution of 2.14. The limits of quantification were 0.25 pmol per injection for NBD-PZ-D-2-HG and-L-2-HG. The precision values were below 6.58%, and the accuracies were 88.2-92.8%. The intracellular concentrations of D-2-HG and L-2-HG in the cancer cells were 13.5 ± 0.4 and 9.9 ± 0.3 pmol per 1.0 × 10 cells, respectively. The developed method will be useful for elucidating the role of 2-HG enantiomers in cancer cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/d3ay00263b | DOI Listing |
Heliyon
January 2024
Department of Pharmacy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
"Oncometabolite" 2-hydroxyglutarate (2-HG) is an aberrant metabolite found in tumor cells, exerting a pivotal influence on tumor progression. Recent studies have unveiled its impact on the proliferation, activation, and differentiation of anti-tumor T cells. Moreover, 2-HG regulates the function of innate immune components, including macrophages, dendritic cells, natural killer cells, and the complement system.
View Article and Find Full Text PDFAnal Methods
June 2023
Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.
D-2-Hydroxyglutarate (D-2-HG) is an oncometabolite that induces cancer cell survival and growth. D-2-HG is produced by mutations in isocitrate dehydrogenases 1 and 2. L-2-HG has different roles than the D-form, and chiral discrimination is important for elucidating the exact roles of the 2-HG enantiomers.
View Article and Find Full Text PDFNat Protoc
April 2023
Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.
Analytical techniques with high sensitivity and selectivity are essential to the quantitative analysis of clinical samples. Liquid chromatography coupled to tandem mass spectrometry is the gold standard in clinical chemistry. However, tandem mass spectrometers come at high capital expenditure and maintenance costs.
View Article and Find Full Text PDFBiochimie
April 2023
Programa de Pós-Graduação Em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil; Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil; Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil. Electronic address:
Accumulation of D-2-hydroxyglutaric acid (D-2-HG) is the biochemical hallmark of D-2-hydroxyglutaric aciduria type I and, particularly, of D-2-hydroxyglutaric aciduria type II (D2HGA2). D2HGA2 is a metabolic inherited disease caused by gain-of-function mutations in the gene isocitrate dehydrogenase 2. It is clinically characterized by neurological abnormalities and a severe cardiomyopathy whose pathogenesis is still poorly established.
View Article and Find Full Text PDFJ Neuropathol Exp Neurol
June 2022
Department of Molecular Medicine, Institute of Health Sciences, Dokuz Eylul University, Izmir, Turkey.
Isocitrate dehydrogenase-1 (IDH1) mutation is accepted as one of the earliest events in tumorigenesis in gliomas. This mutation causes preferential accumulation of D- relative to L-enantiomer of 2-hydroxyglutarate (2-HG). Minimally invasive techniques to detect IDH1 mutation may prove useful for clinical practice.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!